EP0424193A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Use of actinonin for the manufacture of a medicament for angiogenesis inhibition
Assignee: Microbial Chemistry Research Foundation
•
Filing: 1990-09-21
•
Granted: —
•
Expires: 2010-09-21
Abstract
Abstract Actinonin and a salt thereof are now found to be active as an inhibitor to angiogenesis in a mammal and hence is expectable to be useful as a therapeutic agent for treatment of carcinomas, tumors, diabetic retinopathy and inflammatory response.
Inventors
- 👤 Takao Iwaguchi
- 👤 Mariko Shimamura
- 👤 Shingo Uchida
- 👤 Takaaki Aoyagi
- 👤 Tomio Takeuchi
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-10 01:41
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61P; A61P29/00; A61P3/00; A61P3/08; A61P3/10; A61P35/00
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
39 words
A pharmaceutical composition, useful as an angiogenesis inhibitor, which comprises an effective amount of actinonin or a pharmaceutically acceptable acid addition salt of actinonin as the active ingredient, in association with a pharmaceutically acceptable carrier for the active ingredient.
Claim 2
Dependent Claim
39 words
A pharmaceutical composition, useful as an angiogenesis inhibitor, which comprises an effective amount of actinonin or a pharmaceutically acceptable acid addition salt of actinonin as the active ingredient, in association with a pharmaceutically acceptable carrier for the active ingredient.
Claim 3
Independent Claim
33 words
A method for inhibiting angiogenesis in a mammal, which comprises administering an effective amount of actinonin or a pharmaceutically acceptable acid addition salt of actinonin to a mammal in need of the treatment.
Claim 4
Independent Claim
33 words
A method for inhibiting angiogenesis in a mammal, which comprises administering an effective amount of actinonin or a pharmaceutically acceptable acid addition salt of actinonin to a mammal in need of the treatment.
Claim 5
Dependent Claim
19 words
Use of actinonin or a pharmaceutically acceptable acid addition salt of actinonin in the manufacture of an angiogenesis-inhibiting drug.
Claim 6
Dependent Claim
19 words
Use of actinonin or a pharmaceutically acceptable acid addition salt of actinonin in the manufacture of an angiogenesis-inhibiting drug.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.